Free Trial

Novartis (NVS) Stock Price, News & Analysis

Novartis logo
$121.90 -1.91 (-1.54%)
Closing price 07/3/2025 03:30 PM Eastern
Extended Trading
$123.50 +1.60 (+1.32%)
As of 07/3/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Novartis Stock (NYSE:NVS)

Key Stats

Today's Range
$121.12
$122.53
50-Day Range
$105.18
$123.83
52-Week Range
$96.06
$124.45
Volume
955,240 shs
Average Volume
1.59 million shs
Market Capitalization
$257.50 billion
P/E Ratio
19.05
Dividend Yield
2.12%
Price Target
$123.67
Consensus Rating
Hold

Company Overview

Novartis Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
33rd Percentile Overall Score

NVS MarketRank™: 

Novartis scored higher than 33% of companies evaluated by MarketBeat, and ranked 734th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Novartis has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 6 hold ratings, and 3 sell ratings.

  • Amount of Analyst Coverage

    Novartis has only been the subject of 1 research reports in the past 90 days.

  • Read more about Novartis' stock forecast and price target.
  • Earnings Growth

    Earnings for Novartis are expected to grow by 4.26% in the coming year, from $8.45 to $8.81 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Novartis is 19.05, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.65.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Novartis is 19.05, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.66.

  • Price to Earnings Growth Ratio

    Novartis has a PEG Ratio of 1.68. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Novartis has a P/B Ratio of 5.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Novartis' valuation and earnings.
  • Percentage of Shares Shorted

    0.20% of the float of Novartis has been sold short.
  • Short Interest Ratio / Days to Cover

    Novartis has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Novartis has recently increased by 15.87%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Novartis pays a meaningful dividend of 2.13%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Novartis does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Novartis is 40.47%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Novartis will have a dividend payout ratio of 29.40% next year. This indicates that Novartis will be able to sustain or increase its dividend.

  • Read more about Novartis' dividend.
  • Percentage of Shares Shorted

    0.20% of the float of Novartis has been sold short.
  • Short Interest Ratio / Days to Cover

    Novartis has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Novartis has recently increased by 15.87%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Novartis has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 20 news articles for Novartis this week, compared to 17 articles on an average week.
  • Search Interest

    Only 4 people have searched for NVS on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Novartis to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Novartis insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.01% of the stock of Novartis is held by insiders.

  • Percentage Held by Institutions

    Only 13.12% of the stock of Novartis is held by institutions.

  • Read more about Novartis' insider trading history.
Receive NVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novartis and its competitors with MarketBeat's FREE daily newsletter.

NVS Stock News Headlines

July 4th: 59% dividend from Bitcoin (No Crypto Needed)
I've got something exciting for you this July 4th holiday... How about a 59.07% dividend from Bitcoin? Yes, you read that right. And no, you don't need to buy any cryptocurrency or trade options... Here's the deal: Our July 4th special includes a FREE report on what I call the "Bitcoin Income Vault."
UBS Sticks to Its Hold Rating for Novartis AG (NOVN)
7 Killer European Stocks To Buy In July
See More Headlines

NVS Stock Analysis - Frequently Asked Questions

Novartis' stock was trading at $97.31 on January 1st, 2025. Since then, NVS shares have increased by 25.3% and is now trading at $121.90.

Novartis AG (NYSE:NVS) announced its earnings results on Tuesday, April, 29th. The company reported $2.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.12 by $0.16. The firm's revenue for the quarter was up 11.9% compared to the same quarter last year.
Read the conference call transcript
.

Novartis subsidiaries include these companies: Gyroscope Therapeutics, Arctos Medical, Cellerys, Cadent Therapeutics, Vedere Bio, Vedere Bio ll, Amblyotech, and more.

Novartis' top institutional shareholders include Park National Corp OH, Marotta Asset Management, Cullen Investment Group LTD. and Arvest Investments Inc..

Shares of NVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Novartis investors own include BlackRock (BLK), Broadcom (AVGO), UnitedHealth Group (UNH), ServiceNow (NOW), Humana (HUM), TotalEnergies (TTE) and American Water Works (AWK).

Company Calendar

Last Earnings
4/29/2025
Today
7/06/2025
Next Earnings (Estimated)
7/17/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Large Cap Pharma
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSE:NVS
Employees
75,883
Year Founded
1996

Price Target and Rating

Average Stock Price Target
$123.67
High Stock Price Target
$130.00
Low Stock Price Target
$120.00
Potential Upside/Downside
+1.4%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
11 Analysts

Profitability

Trailing P/E Ratio
19.05
Forward P/E Ratio
14.43
P/E Growth
1.68
Net Income
$11.94 billion
Pretax Margin
28.64%

Debt

Sales & Book Value

Annual Sales
$53.22 billion
Cash Flow
$10.70 per share
Price / Cash Flow
11.39
Book Value
$21.59 per share
Price / Book
5.65

Miscellaneous

Outstanding Shares
2,112,422,000
Free Float
2,112,211,000
Market Cap
$257.50 billion
Optionable
Optionable
Beta
0.59

Social Links

A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NYSE:NVS) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners